Interrogation ofERGgene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome

2013 ◽  
Vol 113 (2) ◽  
pp. 309-319 ◽  
Author(s):  
Tarek A. Bismar ◽  
Mohammed Alshalalfa ◽  
Lars F. Petersen ◽  
Liang Hong Teng ◽  
Travis Gerke ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Gene Signature ◽  
Relevant Implication

Association of neuroendocrine (NE) mRNA expression profiling in hormone-sensitive tumors samples with adverse clinical outcome in castration-resistant prostate cancer (CRPC) patients.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 165-165
Author(s):  
Mayra Orrillo ◽  
Natalia Jimenez ◽  
Oscar Reig ◽  
Giancarlo Castellano ◽  
Albert Font ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Treatment Strategies ◽  
Gene Signature ◽  
Molecular Profile ◽  
Castration Resistant Prostate Cancer ◽  
Adverse Clinical Outcome ◽  
Related Gene ◽  
Primary Tumors ◽  
Hormone Sensitive

165 Background: NE dedifferentiation is associated to clinical aggressiveness and resistance to androgen receptor inhibition in prostate cancer. We investigated impact of a NE expression signature in the clinical outcome of mCRPC patients treated with taxanes. Methods: This is a multicenter retrospective study. A customized panel of 45 NE-related gene signature was tested in total RNA from formalin-fixed paraffin-embedded hormone-sensitive tumor samples, by the nCounter platform (Nanostring Technologies). Patients were grouped according to their molecular profile by unsupervised clustering. Expression levels were correlated with taxanes response and clinical outcome. Independent association with survival was evaluated by multivariate Cox modeling. Results: Eighty seven patients were included in the study, 79 were treated with docetaxel and 8 with cabazitaxel. Median age was 64.8 (44-88.3) years and median follow-up was 20.7 (1.17-74.4) months. High expression of the NE signature was associated with a shorter time of CRPC development (N=60, median 12.8 vs 21.6, HR 2.4, 95%CI 1.3-4.3, P=0.003) and shorter OS from CRPC diagnosis (median 24.1 vs 41.33, HR 2.3, 95%CI 1.4-3.8, P=0.001). Moreover, according to the outcome to taxanes, high NE signature correlated with lower PSA-PFS (median 6.6 vs 10.1 mo P=0.047, HR 1.6, 95%CI 1-2.7, P=0.05) and OS (median 19 vs 22 mo, HR 1.8, 95%CI 1.1-2.8, P=0.014), and it was independently associated to a lower OS (HR 1.9, 95%CI 1.1-3.2, P=0.016). Conclusions: NE-related gene expression in hormone-sensitive tumor samples is associated with adverse clinical outcome and lower taxane benefit in metastatic CRPC patients. Thus, molecular characterization of primary tumors may be useful to guide treatment strategies in metastatic prostate cancer.

Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer

2012 ◽  
Vol 10 (2) ◽  
pp. 91-99 ◽  
Author(s):  
Pamela McCall ◽  
Jamie Catlow ◽  
Peter A McArdle ◽  
Donald C McMillan ◽  
Joanne Edwards
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Nuclear Factor Kappa B ◽  
Nuclear Factor ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Nuclear Factor Kappa

scholarly journals A novel embryonic plasticity gene signature that predicts metastatic competence and clinical outcome

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Rama Soundararajan ◽  
Anurag N. Paranjape ◽  
Valentin Barsan ◽  
Jeffrey T. Chang ◽  
Sendurai A. Mani
Keyword(s):  
Clinical Outcome ◽  
Gene Signature

scholarly journals EP-1555: Multiple re-irradiation for locally recurrent prostate cancer: proof of concept and clinical outcome

2018 ◽  
Vol 127 ◽  
pp. S839
Author(s):  
S. Volpe ◽  
B.A. Jereczek Fossa ◽  
D. Zerini ◽  
D.P. Rojas ◽  
C. Fodor ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Proof Of Concept ◽  
Recurrent Prostate Cancer ◽  
Locally Recurrent
Sign in / Sign up

Export Citation Format

Share Document